Nuvalent reports positive data from Phase I/II NSCLC therapy trial

Nuvalent has reported positive preliminary data from the Phase I dose-escalation part of the ARROS-1 Phase I/II clinical trial of NVL-520 in advanced ROS1-positive non-small cell lung cancer (NSCLC) and various other solid tumour patients.